| Literature DB >> 31789599 |
Amanda Johnson1, Fan Yang2, Siddharth Gollarahalli3, Tanvi Banerjee2, Daniel Abrams4, Jude Jonassaint5, Charles Jonassaint5, Nirmish Shah6.
Abstract
BACKGROUND: Sickle cell disease (SCD) is an inherited red blood cell disorder affecting millions worldwide, and it results in many potential medical complications throughout the life course. The hallmark of SCD is pain. Many patients experience daily chronic pain as well as intermittent, unpredictable acute vaso-occlusive painful episodes called pain crises. These pain crises often require acute medical care through the day hospital or emergency department. Following presentation, a number of these patients are subsequently admitted with continued efforts of treatment focused on palliative pain control and hydration for management. Mitigating pain crises is challenging for both the patients and their providers, given the perceived unpredictability and subjective nature of pain.Entities:
Keywords: SCD; machine learning; pain; sickle cell disease
Year: 2019 PMID: 31789599 PMCID: PMC6915456 DOI: 10.2196/13671
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
List of features extracted from wearable signals.
| Feature | Description |
| Mean | Average value of the signal |
| Standard deviation | Amount of variation of the signal |
| Mean of derivative | Average rate of change of the signal |
| RMSa | Square root of the mean of the squares of a set of values |
| Peak to peak | Difference between the maximum and minimum peak |
| Peak to RMS | The ratio of the largest absolute value to the RMS value |
| Number of peaks | Number of local maximums (peaks) |
| Power | Sum of the absolute squares of time-domain samples divided by the length |
aRMS: root mean square.
Signals and reduced feature sets.
| Signal | Feature | |
| Forward selection | Backward elimination | |
| Heart rate |
Mean of derivative Number of peaks |
Power |
| R-R interval |
Number of peaks |
Standard deviation Peak to RMSa |
| Galvanic skin response |
Mean Peak to RMS |
Mean Peak to peak |
| Steps |
Mean RMS Peak to peak |
Number of peaks Power |
| Skin temperature |
Peak to RMS |
Power Mean of derivative Number of peaks |
| Angular velocity in Y direction | —b |
RMS Number of peaks |
| Angular velocity in Z direction | — |
Peak to RMS Number of peaks |
aRMS: root mean square.
bNot applicable
Patient demographics.
| Patient | Age (years) | Sex | Sickle cell disease type | Insurance | Medications | Emergency department visits in prior year | Day hospital visits in prior year | Inpatient stays in prior year |
| 1 | 21 | Fa | SCb | Publicc | Dilaudid 6 mg; Oxycodone 5 mg | 11 | 1 | 1 |
| 2 | 25 | F | SSd | Public | Dilaudid 8 mg | 3 | 8 | 3 |
| 3 | 24 | F | SC | Private | Dilaudid 8 mg | 1 | 4 | 3 |
| 4 | 40 | Me | SS | Public | Dilaudid 16 mg; Oxycodone 5 mg | 0 | 4 | 0 |
| 5 | 48 | M | SB+f | Public | Dilaudid 9 mg | 3 | 2 | 2 |
| 6 | 39 | M | SS alphag | Public | Dilaudid 12 mg | 1 | 3 | 0 |
| 7 | 37 | F | SC | Public | Dilaudid 9 mg | 1 | 3 | 1 |
| 8 | 38 | F | SC | Public | Dilaudid 8 mg | 1 | 10 | 2 |
| 9g | 21 | M | SS | Public | Dilaudid 4 mg; Dilaudid PCAh | 14 | 19 | 14 |
| 10 | 28 | F | SS | Public | Dilaudid 16 mg; Oxycodone 20 mg | 5 | 8 | 16 |
| 11 | 36 | M | SS | Public | Dilaudid 6 mg | 23 | 1 | 17 |
| 12 | 66 | M | SS | Public | Dilaudid 8 mg; Morphine 4 mg | 0 | 0 | 0 |
| 13 | 44 | M | SC | Public | Dilaudid 11 mg | 10 | 12 | 6 |
| 14 | 28 | F | SB0i | Public | Dilaudid 8 mg | 19 | 7 | 12 |
| 15 | 20 | F | SC | Public | Dilaudid 9 mg | 18 | 6 | 10 |
| 16 | 26 | F | SS | Public | Dilaudid 13 mg | 12 | 30 | 4 |
| 17 | 38 | F | SS | Public | Dilaudid 16 mg | 0 | 22 | 2 |
| 18 | 22 | M | SC | Private | Dilaudid 8 mg | 51 | 8 | 3 |
| 19 | 28 | M | SC | Public | Dilaudid 8 mg; Oxycodone 10 mg | 7 | 4 | 8 |
| 20 | 21 | F | SS | Public | Dilaudid 5 mg; Oxycodone 10 mg | 0 | 10 | 7 |
aF: female.
bSC: type SC (hemoglobin S and hemoglobin C).
cPublic: at least some portion of insurance is Medicare or Medicaid.
dSS: type SS (hemoglobin S and hemoglobin S).
eM: male.
fSB+: type S beta thalassemia plus (hemoglobin S and beta thalassemia plus).
gSS alpha: type SS with alpha thalassemia (hemoglobin S and hemoglobin S with alpha thalassemia).
hPCA: patient-controlled analgesia.
iSB0: type S beta thalassemia zero (hemoglobin S and beta thalassemia zero).
Algorithm performances on 2 reduced feature sets using 4 regression methods.
| Regression algorithm | Forward selection feature set | Backward elimination feature set | ||
|
| RMSEa | Correlation | RMSE | Correlation |
| Ridge | 1.853 | 0.381 | 1.844 | 0.370 |
| Lasso | 1.871 | 0.358 | 1.891 | 0.370 |
| Gaussian process for regression | 1.764 | 0.475 | 1.473 | 0.683 |
| Support vector machines for regression | 1.721 | 0.522 | 1.430b | 0.706b |
aRMSE: root mean square error.
bBest performed model as described in the text.
Figure 1Scatter plot of the predicted and actual pain scores using the support vector machines for regression model.
Figure 2Plot of the residuals versus predicted pain scores using the backward elimination feature set.
Figure 5Plot of the residuals versus predicted pain scores using the backward elimination feature set (support vector machines for regression).
Figure 3Plot of the residuals versus predicted pain scores using the backward elimination feature set (lasso).
Figure 4Plot of the residuals versus predicted pain scores using the backward elimination feature set (gaussian process for regression).
Prediction performances on the 4-level pain scale using support vector machines for regression and support vector machines.
| Algorithm | Accuracy | F1 score of no pain | F1 score of mild pain | F1 score of moderate pain | F1 score of severe pain | Weighted F1 score |
| Support vector machines | 0.682 | 0 | 0 | 0.537 | 0.786 | 0.663 |
| Support vector machines for regression | 0.729a | 0 | 0.286 | 0.675 | 0.803 | 0.728a |
aBest performed model as described in the text.